Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions
- PMID: 10944369
- DOI: 10.1067/mob.2000.107950
Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions
Abstract
Mifepristone at a dose of 600 mg followed by 400 microg misoprostol orally has been used for early abortion by hundreds of thousands of women with success rates at </=49 days' gestation ranging from 92% to 97%. Newer regimens may prove simpler than this standard regimen and may serve a larger number of patients. Vaginal rather than oral administration of misoprostol may have advantages, including improvement in the efficacy of mifepristone regimens at >49 days' gestation. A lower mifepristone dose of 200 mg and in-home self-administration of misoprostol both appear safe and effective. Although most research protocols have used ultrasonography to confirm gestational age, the method can be provided safely without routine reliance on ultrasonography. Acceptability of the method to care providers and to patients has been high in all studies. The introduction of medical abortion into general medical practice in the United States will teach us much about the practical aspects of service provision.
Similar articles
-
Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.Contraception. 1999 Jan;59(1):1-6. doi: 10.1016/s0010-7824(98)00150-4. Contraception. 1999. PMID: 10342079 Clinical Trial.
-
Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol.Lancet. 1998 Aug 15;352(9127):542-3. doi: 10.1016/S0140-6736(05)79250-3. Lancet. 1998. PMID: 9716062
-
Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.Hum Reprod. 1995 Jun;10(6):1521-7. doi: 10.1093/humrep/10.6.1521. Hum Reprod. 1995. PMID: 7593528 Clinical Trial.
-
Alternatives to mifepristone regimens for medical abortion.Am J Obstet Gynecol. 2000 Aug;183(2 Suppl):S54-64. doi: 10.1067/mob.2000.107949. Am J Obstet Gynecol. 2000. PMID: 10944370 Review.
-
Current medical abortion care.Curr Womens Health Rep. 2003 Dec;3(6):461-9. Curr Womens Health Rep. 2003. PMID: 14613667 Review.
Cited by
-
Mifepristone (RU-486®) as a Schedule IV Controlled Drug-Implications for a Misleading Drug Policy on Women's Health Care.Int J Environ Res Public Health. 2022 Jul 8;19(14):8363. doi: 10.3390/ijerph19148363. Int J Environ Res Public Health. 2022. PMID: 35886217 Free PMC article.
-
Exploring the impact of mifepristone's risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics✰,✰✰.Contraception. 2022 May;109:19-24. doi: 10.1016/j.contraception.2022.01.017. Epub 2022 Feb 4. Contraception. 2022. PMID: 35131289 Free PMC article.
-
Medical abortions among university students in Ghana: implications for reproductive health education and management.Int J Womens Health. 2018 Sep 5;10:515-522. doi: 10.2147/IJWH.S160297. eCollection 2018. Int J Womens Health. 2018. PMID: 30233253 Free PMC article.
-
The incidence of induced abortion in Kinshasa, Democratic Republic of Congo, 2016.PLoS One. 2017 Oct 2;12(10):e0184389. doi: 10.1371/journal.pone.0184389. eCollection 2017. PLoS One. 2017. PMID: 28968414 Free PMC article.
-
Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study.PLoS Med. 2016 Aug 30;13(8):e1002110. doi: 10.1371/journal.pmed.1002110. eCollection 2016 Aug. PLoS Med. 2016. PMID: 27575488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical